The first reductions took effect yesterday, December 25, for the prostate cancer treatment Erleada (apalutamide) and the anti-TNF alpha Simponi (golimumab).
The bulk of the price reductions will apply to January 2, 2025 and will concern a total of around fifty originators. THE Official Journal of December 20, 2024 thus cites the anti-IL-1 Ilaris (canakinumab), the treatment of multiple sclerosis Kesimpta (ofatumumab), the anticancer drugs Tafinlar (dabrafenib), Mekinist (trametinib) or Tasigna (nilotinib), but also Xolair (omalizumabb) and Trimbow (beclometasone, formoterol, glycopyrronium). Another text also announces a reduction for the levonorgestrel intrauterine devices Mirena, Jaydess and Kyleena and the anticancer drugs Braftovi 50 mg (encorafenib) and Mektovi (binimetinib). The anti-IL-12 and IL-23 Stelara (ustekinumab), the enoxaparin Inhixa, the antidepressant Valdoxan (agomelatine), the beclometasone Beclospin and the inhalation suspension Seretide (fluticasone, salmeterol) appear, among others, in a third text from this same Journal.
Texts published on December 24 indicate a reduction in prices on January 2 for, in particular, the eye drops Combigan (brimonodine, timolol) and Lumigan (bimatoprost), the pulmonology drugs Spiolto (tiotropium, olodaterol), Spiriva (tiotropium) and Striverdi ( olodaterol) Respimat (text 112), treatment of multiple sclerosis Ponvory (ponesimod), the anti-HIV Delstrigo (doravirine, lamivudine, tenofovir disoproxil), or the anti-cancer drug Ibrance (palbociclib) and the treatment of benign prostatic hypertrophy based on Serenoa repens Permixon (text 117).
Two price increases
Vitamin B12 Delagrange (cyanocobalamin) will increase by almost 16% from January 6, to reach €2.26. And on January 15, Monoox eye drops (cifloxacin) will see its price excluding dispensing fees increase from €2.93 to €3.07, an increase of 5%.
Drops to come
Au 1is A price reduction for aflibercept Eylea is already planned for February 2025. The topical Nerisone (diflucortolone) and the anticancer drugs Braftovi 75 mg (encorafenib) and Votrient (pazopanib) will follow suit on 1is March, of the same as the somatropin Genotonorm and Omnitrope as well as the anti-JAK drug Xeljanz (tofacitinib).
Forecast stocks
As a reminder, pharmacists have 38 days from the date of application of the new prices to sell their stock at the old price. This deadline is set at 20 days for wholesalers-distributors.
